<DOC>
	<DOCNO>NCT02648672</DOCNO>
	<brief_summary>This randomize double-blind ( investigator subject blind ) , placebo control ascend single dose study evaluate safety , tolerability , pharmacokinetic profile BPN14770 healthy male female subject . Each subject randomize receive either single dose BPN14770 placebo .</brief_summary>
	<brief_title>BPN14770 Single Ascending Dose Study Healthy Male Female Subjects</brief_title>
	<detailed_description>Objectives : 1 . To evaluate safety tolerability profile single oral ascend dose level BPN14770 healthy subject . 2 . To characterize BPN14770 plasma pharmacokinetic profile follow oral administration .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Healthy male female . Female subject must pregnant breastfeeding . 2 . Subject must 18 55 year age ( inclusive ) . 3 . Subject 's body mass index ( BMI ) must 18 32 kg/m2 ( inclusive ) , subject must weigh minimum 50 kg ( 110 lb ) . 4 . Female subject must surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy least 6 month prior dose ) least 2 year postmenopausal . Menopausal status verify folliclestimulating hormone ( FSH ) test screening . In addition , female must negative pregnancy test result within 48 hour study drug administration regardless childbearing potential . 5 . Male subject must willing inform female partner participation study use adequate contraceptive method ( must vasectomy least 6 month prior dose use least one barrier method birth control ) . 6 . Subject must understand study procedure , voluntarily consent participate study , provide write informed consent prior start studyspecific procedure . 7 . Subject willing able remain study unit entire duration confinement period return outpatient visit . 1 . Clinically significant abnormality investigator 's opinion indicate current hematology , biochemistry , urinalysis test , medical history , social history , vital sign , physical examination . 2 . Positive serology result hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) . 3 . Marked hypotension ( systolic blood pressure [ BP ] ˂90 mmHg diastolic BP ˂50 mmHg ) hypertension ( systolic BP ˃160 mmHg diastolic BP ˃100 mmHg ) base supine sit value screen predose . Outofrange vital sign may repeat . 4 . Marked bradycardia ( heart rate ˂45 beat per minute [ bpm ] ) tachycardia ( heart rate ˃110 bpm ) base supine , sit , ECG value screen predose . Outofrange vital sign may repeat . 5 . Current past history cardiovascular , cerebrovascular , pulmonary , renal , liver disease . 6 . History hematological disorder ( e.g. , thrombocytopenia ) immediate family ( i.e , parent sibling ) . 7 . Clinically important significant conduction abnormality average triplicate ECGs ( include QTc interval ˃450 msec ) ; evidence history long QT syndrome . This exclusion apply ECGs take screening , Day 1 , Day 1 predose . 8 . Current past history gastric duodenal ulcer diseases gastrointestinal tract could interfere absorption study drug . Note : Subject history appendectomy cholecystectomy may enrol . 9 . Active acute chronic infectious disease . 10 . Unable discontinue counter ( OTC ) medication utilized regular basis take prescription medication within 14 day prior admission study Day 2 . 11 . Regular ( daily ) consumption alcohol exceed two serving beer equivalent amount form alcohol ( 1 serve = 12 oz beer , 5.0 oz wine , 1.5 oz distil spirit ) . 12 . Any history alcohol drug abuse within previous year prior Screening Visit ( per current edition Diagnostic Statistical Manual Mental Disorders , 5th Edition : DSM5 ) . 13 . Any use alcohol within 48 hour admission study Day 2 . 14 . Active smoker tobacco user ( e.g. , chew snuff ) unable discontinue tobacco use least 6 month prior admission study Day 2 refrain use tobacco study treatment evaluation period . 15 . Inability unwillingness comply protocol rule clinical research unit , likely inability complete study . 16 . Participation clinical study involve investigational drug within previous 30 day prior Screening Visit . 17 . Donation blood blood product ( include plasma ) 8 week first administration study drug Day 1 . 18 . Positive screen drug abuse . 19 . History allergy penicillin sulfonamide , clinically significant drug allergy include symptom shortness breath , rash , edema .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>